Foundayo vs Mounjaro
Eli Lilly's Oral Pill vs Its Tirzepatide Injection (2026)
Mounjaro and Zepbound are the same drug (tirzepatide) under different brands — Mounjaro for type 2 diabetes, Zepbound for obesity. This page compares Eli Lilly's injectable tirzepatide (Mounjaro) with its new oral GLP-1 pill, Foundayo (orforglipron): convenience, blood-sugar and weight effects, and cost.
Foundayo vs Mounjaro: At a Glance
- ✓Non-peptide oral GLP-1 pill (GLP-1 only)
- ✓Once daily — any time, with or without food
- ✓Approved for weight management (obesity)
- ✓Phase 2 ~14.7% weight loss; lowers HbA1c (ACHIEVE)
- ✓No needles; room-temperature storage
- ✓Eli Lilly — FDA approved April 2026
- ✓Dual GLP-1/GIP injectable
- ✓Once-weekly subcutaneous injection
- ✓Approved for type 2 diabetes (Zepbound = obesity twin)
- ✓SURPASS: strong HbA1c reduction; large weight loss
- ✓Refrigerated; injection-site rotation needed
- ✓Eli Lilly — widely available now
Detailed Comparison
| Feature | Foundayo (Orforglipron) | Mounjaro (Tirzepatide) |
|---|---|---|
| Manufacturer | Eli Lilly | Eli LillyBest |
| Drug Type | Non-peptide small molecule | Peptide dual agonist |
| Mechanism | GLP-1 only | GLP-1 + GIP |
| Primary Indication | Weight management (obesity) | Type 2 diabetes |
| Administration | Once-daily pill | Once-weekly injection |
| Weight Loss | Phase 2 ~14.7%; up to 27.3 lbs | Large (tirzepatide; ~15–21% range) |
| Blood Sugar | Lowers HbA1c (ACHIEVE program) | Strong HbA1c reduction (SURPASS) |
| Storage | Room temperature | Refrigerated until use |
| Needles | No | Yes (weekly) |
| FDA Status | Approved April 2026 | Approved (diabetes 2022) |
How to Choose
Diabetes-First
Mounjaro is FDA-approved for type 2 diabetes with strong HbA1c data (SURPASS). If glucose control is the main goal, it has the on-label record.
Weight-First, No Needles
Foundayo is built for weight management as an oral pill. For weight loss without injections, it is the convenient choice.
Maximum Power
Tirzepatide's dual GLP-1/GIP mechanism generally produces larger weight loss and glucose lowering than a GLP-1-only pill.
Storage & Travel
Foundayo is room-temperature; Mounjaro needs refrigeration. Foundayo is easier to travel with.
Routine
A daily pill (Foundayo) vs a weekly shot (Mounjaro). Choose the cadence you will actually maintain.
Cost & Coverage
Coverage differs by indication. Foundayo self-pay starts ~$149/mo (lowest dose). Check savings programs for both.
The Bottom Line
Mounjaro is tirzepatide branded for type 2 diabetes — the same molecule as Zepbound, which is branded for obesity. Compared with Foundayo, the trade-offs mirror the Foundayo-vs-Zepbound decision: tirzepatide is the more powerful, dual-mechanism injectable; Foundayo is the convenient, needle-free oral GLP-1.
If your primary issue is diabetes and glucose control, Mounjaro has the on-label evidence and a strong HbA1c track record. If your primary issue is weight and you want a pill, Foundayo is purpose-built and far simpler to take — no needles, no refrigeration, no timing rules.
For many people both effects matter, and the right answer depends on which goal leads and how you feel about injections. Whichever you take, track your dose, weight, and glucose in Shotlee so you and your prescriber can judge the result on real data.
Foundayo vs Mounjaro: Frequently Asked Questions
Mounjaro (tirzepatide) is the more powerful drug thanks to its dual GLP-1/GIP mechanism, with strong weight loss and HbA1c reduction. Foundayo (orforglipron) is a needle-free oral GLP-1 with ~14.7% weight loss in Phase 2. Mounjaro is stronger; Foundayo is more convenient.
Yes, both are Eli Lilly products. Foundayo is the oral orforglipron pill; Mounjaro is injectable tirzepatide (the same molecule as Zepbound, which is branded for obesity).
Mounjaro is FDA-approved for type 2 diabetes. The same drug, tirzepatide, is branded as Zepbound for obesity. Foundayo is approved for weight management.
No. Foundayo is a once-daily oral pill taken any time. Mounjaro is a once-weekly subcutaneous injection that requires refrigeration and injection-site rotation.
Yes. Shotlee tracks oral and injectable GLP-1s — dose, weight, glucose, and side effects — so you can compare them on your own data.
Track Foundayo or Mounjaro in Shotlee
Free dose logging, weight trends, glucose, and side-effect tracking for oral and injectable GLP-1s.
📚References & sources
Latest on Foundayo
Eli Lilly's Foundayo: A New Daily Pill Outperforming Oral Semaglutide
A groundbreaking Phase 3 trial reveals that Eli Lilly's new daily oral medication, orforglipron (Foundayo), demonstrates superior efficacy in lowering blood sugar and promoting weight loss compared to existing oral semaglutide treatments for individuals with Type 2 diabetes. This development marks a significant step forward in non-injectable peptide therapies for metabolic health.
6 min read
Eli Lilly's $4.5 Billion Expansion: Fueling the Future of Weight Loss & Health
Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.
6 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read